Which has higher earnings and valuation, AURA or IPHA?

Innate Pharma has higher revenue and earnings than Aura Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.75 N/A Innate Pharma $10.19M 23.13 -$55.64M N/A N/A

Is AURA or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Innate Pharma N/A N/A N/A

Does the media prefer AURA or IPHA?

In the previous week, Aura Biosciences had 6 more articles in the media than Innate Pharma. MarketBeat recorded 7 mentions for Aura Biosciences and 1 mentions for Innate Pharma. Aura Biosciences' average media sentiment score of 1.28 beat Innate Pharma's score of 0.97 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, PHAR or IPHA?

Pharming Group has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $376.13M 2.16 $2.85M $0.12 95.50 Innate Pharma $10.19M 23.13 -$55.64M N/A N/A

Does the media prefer PHAR or IPHA?

In the previous week, Pharming Group and Pharming Group both had 1 articles in the media. Pharming Group's average media sentiment score of 1.55 beat Innate Pharma's score of 0.97 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SLN or IPHA?

Innate Pharma has higher revenue and earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silence Therapeutics $560K 1,590.19 -$88.61M -$1.28 N/A Innate Pharma $10.19M 23.13 -$55.64M N/A N/A

Does the media prefer SLN or IPHA?

In the previous week, Silence Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Silence Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.97 beat Silence Therapeutics' score of 0.70 indicating that Innate Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IPHA or NGNE?

Innate Pharma has higher revenue and earnings than Neurogene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 23.13 -$55.64M N/A N/A Neurogene $930K 809.22 -$90.35M -$5.03 N/A

Is IPHA or NGNE more profitable?

Innate Pharma's return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Neurogene N/A -45.10% -41.00%

Does the media favor IPHA or NGNE?

In the previous week, Neurogene had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Neurogene and 1 mentions for Innate Pharma. Neurogene's average media sentiment score of 1.48 beat Innate Pharma's score of 0.97 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, STTK or IPHA?

Shattuck Labs has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shattuck Labs $1M 698.51 -$48.81M -$0.51 N/A Innate Pharma $10.19M 23.13 -$55.64M N/A N/A

Is STTK or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Innate Pharma N/A N/A N/A

Does the media refer more to STTK or IPHA?

In the previous week, Shattuck Labs had 5 more articles in the media than Innate Pharma. MarketBeat recorded 6 mentions for Shattuck Labs and 1 mentions for Innate Pharma. Shattuck Labs' average media sentiment score of 1.15 beat Innate Pharma's score of 0.97 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innate Pharma (IPHA) Competitors

$2.11 -0.06 (-2.76%)

As of 09/3/2026 04:00 PM Eastern

Compare

IPHA vs. AURA, PHAR, SLN, NGNE, and STTK

Should you buy Innate Pharma stock or one of its competitors? Innate Pharma's main competitors and comparable companies include Aura Biosciences (AURA), Pharming Group (PHAR), Silence Therapeutics (SLN), Neurogene (NGNE), and Shattuck Labs (STTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Innate Pharma compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

In the previous week, Aura Biosciences had 6 more articles in the media than Innate Pharma. MarketBeat recorded 7 mentions for Aura Biosciences and 1 mentions for Innate Pharma. Aura Biosciences' average media sentiment score of 1.28 beat Innate Pharma's score of 0.97 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma has higher revenue and earnings than Aura Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Innate Pharma	$10.19M	23.13	-$55.64M	N/A	N/A

Aura Biosciences presently has a consensus price target of $17.50, indicating a potential upside of 137.45%. Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 215.96%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innate Pharma's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Innate Pharma	N/A	N/A	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Innate Pharma beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Pharming Group currently has a consensus target price of $38.67, suggesting a potential upside of 237.41%. Innate Pharma has a consensus target price of $6.67, suggesting a potential upside of 215.96%. Given Pharming Group's higher possible upside, research analysts plainly believe Pharming Group is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Pharming Group has a net margin of 2.51% compared to Innate Pharma's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Innate Pharma	N/A	N/A	N/A

Pharming Group has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Pharming Group and Pharming Group both had 1 articles in the media. Pharming Group's average media sentiment score of 1.55 beat Innate Pharma's score of 0.97 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50
Innate Pharma	$10.19M	23.13	-$55.64M	N/A	N/A

Summary

Pharming Group beats Innate Pharma on 7 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Silence Therapeutics currently has a consensus target price of $53.50, suggesting a potential upside of 261.73%. Innate Pharma has a consensus target price of $6.67, suggesting a potential upside of 215.96%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innate Pharma has higher revenue and earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,590.19	-$88.61M	-$1.28	N/A
Innate Pharma	$10.19M	23.13	-$55.64M	N/A	N/A

Innate Pharma has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Innate Pharma's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Innate Pharma	N/A	N/A	N/A

Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Silence Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Silence Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.97 beat Silence Therapeutics' score of 0.70 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innate Pharma beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Innate Pharma compare to Neurogene?

Innate Pharma (NASDAQ:IPHA) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Innate Pharma has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Neurogene	N/A	-45.10%	-41.00%

In the previous week, Neurogene had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Neurogene and 1 mentions for Innate Pharma. Neurogene's average media sentiment score of 1.48 beat Innate Pharma's score of 0.97 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma has higher revenue and earnings than Neurogene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	23.13	-$55.64M	N/A	N/A
Neurogene	$930K	809.22	-$90.35M	-$5.03	N/A

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Innate Pharma presently has a consensus target price of $6.67, suggesting a potential upside of 215.96%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 122.46%. Given Innate Pharma's higher possible upside, research analysts plainly believe Innate Pharma is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Innate Pharma and Neurogene tied by winning 7 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Innate Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Innate Pharma	N/A	N/A	N/A

In the previous week, Shattuck Labs had 5 more articles in the media than Innate Pharma. MarketBeat recorded 6 mentions for Shattuck Labs and 1 mentions for Innate Pharma. Shattuck Labs' average media sentiment score of 1.15 beat Innate Pharma's score of 0.97 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	698.51	-$48.81M	-$0.51	N/A
Innate Pharma	$10.19M	23.13	-$55.64M	N/A	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Shattuck Labs currently has a consensus target price of $12.78, indicating a potential upside of 83.59%. Innate Pharma has a consensus target price of $6.67, indicating a potential upside of 215.96%. Given Innate Pharma's higher possible upside, analysts plainly believe Innate Pharma is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Shattuck Labs beats Innate Pharma on 9 of the 14 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$242.43M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.28	25.38
Price / Sales	23.13	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-8.12	16.29	12.89	6.14
Net Income	-$55.64M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-4.95%	0.34%	0.61%	-0.27%
1 Month Performance	18.21%	8.52%	5.73%	0.68%
1 Year Performance	0.48%	52.66%	25.37%	14.84%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	3.5443 of 5 stars	$2.11 -2.8%	$6.67 +216.0%	+4.5%	$242.43M	$10.19M	N/A	220	Short Interest Increase
AURA Aura Biosciences	2.7135 of 5 stars	$7.82 -1.0%	$17.50 +123.8%	+16.2%	$819.27M	N/A	N/A	50	Positive News
PHAR Pharming Group	3.7828 of 5 stars	$11.91 +3.9%	$38.67 +224.7%	-20.2%	$811.12M	$376.13M	99.23	280	Positive News
SLN Silence Therapeutics	2.5515 of 5 stars	$13.67 +2.9%	$53.50 +291.4%	+195.2%	$800.18M	$560K	N/A	100
NGNE Neurogene	2.6243 of 5 stars	$40.84 +3.0%	$83.67 +104.9%	+89.3%	$793.25M	$930K	N/A	90	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. AURA, PHAR, SLN, NGNE, and STTK

How does Innate Pharma compare to Aura Biosciences?

Summary

How does Innate Pharma compare to Pharming Group?

Summary

How does Innate Pharma compare to Silence Therapeutics?

Summary

How does Innate Pharma compare to Neurogene?

Summary

How does Innate Pharma compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. AURA, PHAR, SLN, NGNE, and STTK

How does Innate Pharma compare to Aura Biosciences?

Which has more volatility & risk, AURA or IPHA?

Does the media prefer AURA or IPHA?

Which has higher earnings and valuation, AURA or IPHA?

Do analysts rate AURA or IPHA?

Is AURA or IPHA more profitable?

Do insiders and institutionals have more ownership in AURA or IPHA?

Summary

How does Innate Pharma compare to Pharming Group?

Do analysts recommend PHAR or IPHA?

Is PHAR or IPHA more profitable?

Which has more risk & volatility, PHAR or IPHA?

Does the media prefer PHAR or IPHA?

Do institutionals and insiders hold more shares of PHAR or IPHA?

Which has better valuation & earnings, PHAR or IPHA?

Summary

How does Innate Pharma compare to Silence Therapeutics?

Do analysts recommend SLN or IPHA?

Which has stronger valuation and earnings, SLN or IPHA?

Is SLN or IPHA more profitable?

Which has more risk and volatility, SLN or IPHA?

Do insiders & institutionals hold more shares of SLN or IPHA?

Does the media prefer SLN or IPHA?

Summary

How does Innate Pharma compare to Neurogene?

Which has more volatility and risk, IPHA or NGNE?

Is IPHA or NGNE more profitable?

Does the media favor IPHA or NGNE?

Which has preferable valuation and earnings, IPHA or NGNE?

Do institutionals & insiders hold more shares of IPHA or NGNE?

Do analysts rate IPHA or NGNE?

Summary

How does Innate Pharma compare to Shattuck Labs?

Is STTK or IPHA more profitable?

Does the media refer more to STTK or IPHA?

Which has stronger valuation and earnings, STTK or IPHA?

Do institutionals and insiders have more ownership in STTK or IPHA?

Which has more volatility & risk, STTK or IPHA?

Do analysts rate STTK or IPHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools